These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23748345)

  • 1. Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.
    Yuan LL; Green AS; Bertoli S; Grimal F; Mansat-De Mas V; Dozier C; Tamburini J; Récher C; Didier C; Manenti S
    Leukemia; 2014 Feb; 28(2):293-301. PubMed ID: 23748345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
    Natarajan K; Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
    PLoS One; 2013; 8(9):e74653. PubMed ID: 24040307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia.
    Yuan LL; Green A; David L; Dozier C; Récher C; Didier C; Tamburini J; Manenti S
    Leuk Res; 2014 Nov; 38(11):1342-9. PubMed ID: 25281057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
    Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M
    Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 7. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
    Grundler R; Brault L; Gasser C; Bullock AN; Dechow T; Woetzel S; Pogacic V; Villa A; Ehret S; Berridge G; Spoo A; Dierks C; Biondi A; Knapp S; Duyster J; Schwaller J
    J Exp Med; 2009 Aug; 206(9):1957-70. PubMed ID: 19687226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
    Takami M; Katayama K; Noguchi K; Sugimoto Y
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1364-1371. PubMed ID: 30017192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
    Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
    Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells.
    Zhang Y; Yuan L
    Sci Rep; 2021 Jun; 11(1):13236. PubMed ID: 34168220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
    Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
    Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
    Yao Q; Weigel B; Kersey J
    Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
    Scarpa M; Singh P; Bailey CM; Lee JK; Kapoor S; Lapidus RG; Niyongere S; Sangodkar J; Wang Y; Perrotti D; Narla G; Baer MR
    Mol Cancer Ther; 2021 Apr; 20(4):676-690. PubMed ID: 33568357
    [No Abstract]   [Full Text] [Related]  

  • 18. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
    Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
    Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
    Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
    Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
    Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.